Inhibikase Therapeutics (IKT) EPS (Basic) Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 88.81% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 143.95% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -16.29% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 322.67% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 96.41% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 0.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.15% |
| Mar 31, 2026 | 36.50% |
| Dec 31, 2025 | 15.24% |
| Sep 30, 2025 | 78.94% |
| Jun 30, 2025 | 82.64% |
| Mar 31, 2025 | 78.46% |
| Dec 31, 2024 | 33.97% |
| Sep 30, 2024 | 25.08% |
| Jun 30, 2024 | 41.78% |
| Mar 31, 2024 | 27.14% |
| Dec 31, 2023 | 19.96% |
| Sep 30, 2023 | 17.22% |
| Jun 30, 2023 | -8.25% |
| Mar 31, 2023 | 5.95% |
| Dec 31, 2022 | 37.67% |
| Sep 30, 2022 | -1.76% |
| Jun 30, 2022 | 14.59% |
| Mar 31, 2022 | 29.79% |
| Dec 31, 2021 | -87.54% |
| Sep 30, 2021 | -117.41% |